Carrilizumab adjuvant therapy for advanced non-small cell lung cancer and its effect on tumor markers and safety analysis
Objective:To investigate the adjuvant treatment of advanced non-small cell lung cancer with carrilizumab and its effect on tumor markers and safety.Method:According to random number table method,86 patients with advanced non-small cell lung cancer admitted to our hospital from August 2020 to August 2022 were divided into control group(43 cases receiving pemetrexed disodium + cisplatin injection chemotherapy regimen)and study group(43 cases receiving carrilizumab for injection assisted pemetrexed disodium and cisplatin injection therapy).21 d was one chemotherapy cycle,and the efficacy of patients was evaluated after 3 cycles of treatment.The total clinical response rate,the level of serum tumor markers before and after treatment,the quality-of-life score,and the occurrence of adverse reactions were compared between the two groups.Results:After treatment,the total clinical effectiveness of the study group(65.12%)was higher than that of the control group(41.86%)(P<0.05).Compared with before treatment,the treatment group of serum carbohydrate antigen 125,carcinoembryonic antigen,recombinant cytokeratin fragment antigen,21-1 and neuron-specific enolase were significantly decreased(P<0.05),especially in the study group(P<0.05).Compared with before treatment,the scores of physical function,emotional function,social function,cognitive function and role function were significantly increased in all treatment groups(P<0.05),especially in the study group(P<0.05).There was no significant difference in ADR between the two groups(P>0.05).Conclusions:The application of carrelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer patients is helpful to improve the total clinical response rate,reduce the levels of serum CA125,CEA,CYFRA21-1 and other indicators,improve the quality of life,and does not increase adverse reactions.
NETL
NSTL
万方数据
维普
